1. SCARB2 associates with tumor-infiltrating neutrophils and predicts poor prognosis in breast cancer.
- Author
-
Zhang, Dan, Fang, Jun, Shan, Jiali, Xu, Lijun, Wu, Yunxi, Lu, Bing, Zhang, Xiaojing, Wang, Chongyu, Sun, Pingping, and Wang, Qingqing
- Abstract
Background: The tumor microenvironment (TME) plays a crucial role in various aspects of breast cancer development and metastasis. Nevertheless, the expression, prognostic significance, and correlation with clinical features of SCARB2 in breast cancer, as well as the infiltrative characteristics of TME, remain largely unknown. Methods: We analyzed the differential presentation of SCARB2 mRNA in breast cancer tissues and nontumorous breast tissues and prognosis by The Cancer Genome Atlas (TCGA) and the Genotype-Tissue Expression (GTEx) databases. Additionally, the Tumor Immunity Estimation Resource (TIMER) was taken to evaluate the correlation between SCARB2 mRNA presence and tumor-infiltrating immune cells and immune checkpoints in the TME in breast cancer. We performed multiple immunohistochemical staining to verify the SCARB2 protein expression in breast cancer tissues and its relationship to immune cells and checkpoints and clinicopathological features. Results: We identified elevated SCARB2 expression in breast cancer tissues, and high SCARB2 protein presentation was associated with advanced clinical stage and unfavorable prognosis. In addition, enhanced SCARB2 protein presence was closely correlated with up-regulation CD66b
+ neutrophils infiltration in tumor tissues (r = 0.210, P < 0.05) and CD68+ CD163+ M2 macrophages in the interstitium (r = 0.233, P < 0.05), as well as the immune checkpoints, including PD-1 (r = 0.314, P < 0.01) protein expression. Conclusion: SCARB2 holds promise for predicting the clinical outcome of breast cancer patients and could serve as a potential therapeutic target. [ABSTRACT FROM AUTHOR]- Published
- 2024
- Full Text
- View/download PDF